Hao Wang

US Patent:

20040106773, Jun 3, 2004

Filed:

Nov 6, 2003

Appl. No.:

10/399602

Inventors:

Hao Wang - Rahway NJ, US
Kenneth Koblan - Rahway NJ, US
Hong Sun - Rahway NJ, US
Kimberly Della Penna - Rahway NJ, US

International Classification:

C07K014/47
C07H021/04

US Classification:

530/324000, 536/023500, 435/069100, 435/320100, 435/325000

Abstract:

Disclosed herein are newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide is a human protein, which has been putatively identified as a ligand of a parathyroid hormone receptor homolog, hereinafter referred to as PTH2 Receptor. In particular, the invention relates to isolated nucleic acid molecules, such as DNA and RNA encoding a novel human tuberoinfundibular peptide of 39 residues.

US Patent:

20060205761, Sep 14, 2006

Filed:

Jun 2, 2004

Appl. No.:

10/559701

Inventors:

Catherine Abbadie - Summit NJ, US
Jill Lindia - South Plainfield NJ, US
Hao Wang - Fort Washington PA, US

International Classification:

A61K 31/4745
A61K 31/4709

US Classification:

514300000, 514310000

Abstract:

The invention is directed to methods of treating neuropathic pain and other neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical composition containing CCR-2 antagonists.

US Patent:

20110305685, Dec 15, 2011

Filed:

Feb 26, 2010

Appl. No.:

13/148869

Inventors:

Hao Wang - Los Angeles CA, US
Shutao Wang - Los Angeles CA, US
Helen Su - Torrance CA, US
Caius G. Radu - Los Angeles CA, US
Johannes Czernin - Pacific Palisades CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39/395
C07H 21/00
C08B 37/16
C07H 21/02
C12N 15/63
A61K 38/54
C07K 14/00
C07K 2/00
A61K 31/7088
A61K 38/00
A61P 35/00
A61K 31/724
C07K 16/00
C12N 9/96

US Classification:

4241301, 5303871, 536 231, 536103, 536 245, 4353201, 435188, 530300, 530350, 435325, 514 44 R, 514 44 A, 514 11, 4241781, 5303911, 514 58, 424 943

Abstract:

A supramolecular approach has been developed for preparation of size-controllable nanoparticles, from three different molecular building blocks.

US Patent:

20120003711, Jan 5, 2012

Filed:

Mar 18, 2010

Appl. No.:

13/256879

Inventors:

Shutao Wang - Los Angeles CA, US
Hao Wang - Los Angeles CA, US
Kan Liu - Los Angeles CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 11/02
C12M 1/00
B82Y 99/00

US Classification:

435177, 4352831, 977762, 977904

Abstract:

The present invention provides devices and methods for capturing rare cells. The devices and methods described herein can be used to facilitate the diagnosis and monitoring of metastatic cancers.

US Patent:

20220215633, Jul 7, 2022

Filed:

Jan 7, 2021

Appl. No.:

17/144002

Inventors:

- Mountain View CA, US
Ian Joseph Roth - Brooklyn NY, US
Hao Wang - Long Island City NY, US
Agustin III Olivan Venezuela - Queens NY, US
Subramanian Shyamsunder Mathur - New York NY, US
Xuemei Zhao - Jersey City NJ, US
James Sraw Singh - New York NY, US
Valdrin Koshi - Brooklyn NY, US

International Classification:

G06T 19/00
G06T 15/80
G06F 8/36

Abstract:

Systems and methods for data asset acquisition and obfuscation can be helpful for retrieving augmented reality rendering data assets from third parties. The sending of a software development kit and receiving back data assets can ensure the data assets are compatible with the augmented reality rendering experience in the user interface. The data acquisition system with obfuscation can also ensure the code generated by third parties is stripped of semantics and has reduced readability.

US Patent:

20220180344, Jun 9, 2022

Filed:

Dec 4, 2020

Appl. No.:

17/111887

Inventors:

- Mclean VA, US
John Oliva GILLING - Brooklyn NY, US
Hao WANG - Jersey City NJ, US

International Classification:

G06Q 20/22
G06Q 20/08

Abstract:

In some implementations, a device may receive an indication to create a child account that is associated with the parent account, wherein the parent account is associated with a first entity and the child account is associated with a second entity, and wherein the child account does not have independent resources for completing electronic exchanges. The device may create the child account based on information associated with the parent account. The device may provide information associated with the child account to a platform that enables the second entity to access and interact with the information associated with the child account, wherein the information associated with the child account includes account details associated with the parent account and one or more transactions completed using resources of the parent account.

US Patent:

20230092068, Mar 23, 2023

Filed:

Nov 23, 2022

Appl. No.:

17/993334

Inventors:

- Mountain View CA, US
Ian Joseph Roth - Brooklyn NY, US
Hao Wang - Long Island City NY, US
Agustin III Olivan Venezuela - Queens NY, US
Subramanian Shyamsunder Mathur - New York NY, US
Xuemei Zhao - Jersey City NJ, US
Valdrin Koshi - Brooklyn NY, US
James Sraw Singh - New York NY, US

International Classification:

G06T 19/00
G06F 8/36
G06T 15/80

Abstract:

Systems and methods for data asset acquisition and obfuscation can be helpful for retrieving augmented reality rendering data assets from third parties. The sending of a software development kit and receiving back data assets can ensure the data assets are compatible with the augmented reality rendering experience in the user interface. The data acquisition system with obfuscation can also ensure the code generated by third parties is stripped of semantics and has reduced readability.

US Patent:

20210346344, Nov 11, 2021

Filed:

Jul 26, 2021

Appl. No.:

17/385194

Inventors:

- Rahway NJ, US
Ginny Dai HO - Murray Hill NJ, US
Sookhee N. HA - Warren NJ, US
Sandra J. KOSEOGLU - Fanwood NJ, US
Marc A. LABROLI - West Point PA, US
Sang Ho LEE - Berkeley Heights NJ, US
Mihir MANDAL - Westfield NJ, US
Jianping PAN - Monmouth Junction NJ, US
Weidong PAN - Hillsborough NJ, US
Terry ROEMER - Cranford NJ, US
Jing SU - Scotch Plains NJ, US
Christopher Michael TAN - Scotch Plains NJ, US
Zheng TAN - Westfield NJ, US
Hao WANG - Scotch Plains NJ, US
Christine YANG - New Brunswick NJ, US
Shu-Wei YANG - Edison NJ, US

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ

International Classification:

A61K 31/397
A61P 31/04
A61K 31/407
C07D 235/08
C07D 401/04
C07D 401/14
C07D 403/04
C07D 403/06
C07D 471/04

Abstract:

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.